|
Metabolic disorder | Drug | Effect |
|
Glucometabolic dysfunction | Metformin | ↓ TSH levels in hypothyroid patients |
Pioglitazone | ↓ TSH levels in hypothyroid patients |
Thiazolidinediones | Can induce thyroid-associated orbitopathy |
Cardiometabolic dysfunction | Amiodarone | Can cause both hypothyroidism and thyrotoxicosis |
Beta blockers | ↓ circulating T3 levels |
Prazosin | ↑ TSH, ↑ T4, ↓ T3 |
Sodium nitroprusside | Prevents hypothyroidism in patients undergoing coronary artery bypass grafting |
Barometabolic disorders | Cholestyramine | ↓TH levels; can impair levothyroxine absorption |
Colestipol | Transiently ↓T3 levels in some patients |
Statins | May have antiproliferative effect on thyroid cells; can alter thyroid size; effect of statin is lowered in TD |
Ezetimibe | Enhance conversion of T4 to T3 |
Viscerometabolic disorders | Interferon therapy used in liver and kidney diseases | Thyroid inflammation (both autoimmune and non-autoimmune), and either hyper- or hypothyroidism, which improve following discontinuation of interferon therapy |
Alemtuzumab used as induction agent in renal transplantation | Autoimmune Graves’ disease |
Lenalidomide used in renal cancer therapy | Hypothyroidism or hyperthyroidism |
Sunitinib used in renal cancer therapy | Transient hypothyroidism |
Clomiphene citrate used in PCOS | Associated with increased risk of thyroid cancer |
|